QURE - Baxter was a previously partner with Chatham Therapeutics on their Hemophilia treatments and had previously paid $25 million to Chatham related to the development of those treatments. I assume their relationship was a driving factor to the eventual purchase.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.